Novo Nordisk, driving change to defeat diabetesTime 2020-06-22 08:05:03
Description:Disease experience expert panel (DEEP) People living with a serious chronic disease are experts by experience. By sharing their experience, they help us improve the future of healthcare. Participating in our clinical trials More than 25,000 people participate in our clinical trials each year. They are one of the most important steps to finding new medicines. Sustainable business A sustainable company We believe that a healthy environment, society and economy are fundamental to long-term business success, and we will play our part, also on the long-term. Frequently asked questions Find answers to some of the more frequently asked questions on sustainability and responsible business practices. Our commitment todefeat diabetes From diabetes prevention to ensuring access to care, we are stepping up our efforts to tackle the global diabetes crisis. Learn more about our new Defeat Diabetes strategy With the COVID-19 pandemic escalating, President and chief executive officer of Novo Nordisk, Lars Fruergaard Jørgensen makes the case for resilience, collective action and learning from past experience in the face of an unprecedented challenge. Our commitment to patients, partners and our employees From formulating protein molecules in a tablet to stem cell research, our scientists are always striving for the next breakthrough. Read more about our work in the lab For many people with diabetes, insulin is an essential, life-saving medicine. It’s our ambition that everyone who needs insulin has access to it. Read more about our and affordability programmes Are you looking for information on our US Affordability programs? Please visit NovoCare The huge rise in type 2 diabetes around the world is catastrophic. Uncontrolled, this rise is not sustainable for anyone – people, health systems, businesses or economies. Bending the curve on diabetes is therefore crucial to all of us. Read about our efforts to prevent type 2 diabetes Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Important safety information about colour change for Fiasp® FlexTouch® and Fiasp® Penfill®
<<< Thank you for your visit >>>Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.